CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Unichem Laboratories soars over 7 per cent on getting nod for antidepressant tablets
DSIJ Intelligence
/ Categories: Trending

Unichem Laboratories soars over 7 per cent on getting nod for antidepressant tablets

Unichem Laboratories Limited today announced that it has received ANDA approval for its Amitriptyline HCI tablets from United States Food & Drug Administration (USFDA) to market a generic version of ELAVIL (Amitriptyline Hydrochloride) of AstraZeneca Pharmaceuticals LP.   

Amitriptyline HCI tablets are used for the relief of symptoms of depression. The product will be manufactured in the company‘s Goa plant.   

Reacting to this, the company’s stock today increased by 9.06 per cent and made an intraday high of Rs 364.05 per share. The stock of the company has increased by 191 per cent from its decline in May 2020.   

Unichem Laboratories Ltd is a speciality pharmaceutical company. The company manufactures & markets pharmaceutical formulations branded as generics in several markets across the world. The company deals in product development, process chemistry, and manufacturing complex API as well as dosage forms.   

According to BSE data, the stock traded at a P/E multiple of 56.39 and a price-to-book ratio of 0.89. The stock has a 52-week high and a 52-week low of Rs 364.05 and Rs 121.60, respectively.      

At the time of market closing, the stock of the company was trading at Rs 358.60, up by 7.43 per cent on BSE.

Previous Article Technical Portfolio Guide
Next Article Market news that you should not miss today
Print
837 Rate this article:
5.0
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR